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CD22 is a negative regulator of B-cell receptor signalling
Lars Nitschke, Rita Carsetti, Bettina Ocker, Georges Köhler* and 
Marinus C. Lamers
Background: Antibody responses are triggered by binding of antigen to the
B-cell antigen receptor (BCR). The strength of the resulting signal determines
the outcome of the response, which may vary from the induction of tolerance to
the antigen, to the production of specific high-affinity antibodies. Additional cell-
surface proteins assist the BCR in its function, and can facilitate or inhibit an
antibody response. CD22 is a BCR-associated transmembrane protein, the
cytoplasmic tail of which contains three immunoreceptor tyrosine-based
inhibitory motifs. These motifs are phosphorylated upon BCR-crosslinking, and
can bind the tyrosine phosphatase SHP-1, a putative negative regulator of
signalling from the BCR. In order to assess the role of CD22 in vivo, we have
generated CD22–/– mice by targeted gene inactivation.
Results: In CD22–/– mice, B-cell development is normal. There are normal
numbers of peripheral B cells, but these have a more mature phenotype. In
addition, recirculating B cells are absent from the bone marrow. However, the
distribution of the two B-cell subtypes, B-1 and B-2, is normal. After BCR-
crosslinking in vitro, splenic CD22–/– B cells show an increased Ca2+ influx and
a lower survival due to an increased induction of apoptosis. In contrast, there is
an increased proliferative response to the B-cell mitogen lipopolysaccharide
(LPS). A shorter average lifespan in the B-cell compartment is also found in vivo.
Furthermore, T-cell independent immune responses are impaired, whereas T-cell
dependent responses are normal. 
Conclusions: The absence of CD22 expression lowers the signalling threshold
for BCR-crosslinking and can thus influence the fate of the B cell. We propose
that the low threshold leads to hyperresponsiveness of the B cells and a chronic
basal activation. In this model, engagement of the receptor without T-cell help
leads to an increased induction of apoptosis, thus explaining the shorter lifespan
of CD22–/– B cells and the low response to T-cell independent antigens. The
alteration in B-cell phenotype and the higher levels of LPS-reactivity are
attributable to the chronic basal stimulation.
Background
The B-cell antigen receptor (BCR) on the surface of B
lymphocytes is composed of the antigen receptor chains
in a complex with the membrane-spanning signal-trans-
ducing molecules Iga and Igb. Signal transduction from
the BCR depends on immunoreceptor tyrosine-based
activation motifs (ITAMs) in the cytoplasmic tails of Iga
and Igb which are phosphorylated on tyrosine residues
after BCR crosslinking [1]. Signal-transducing proteins
bind to these phosphorylated tyrosine residues within the
ITAMs, become activated and then trigger signalling cas-
cades. Accessory molecules that modulate signalling
through the BCR have been identified on the surface of B
cells. The CD19/CD21/CD81 complex can positively
modulate BCR signalling [2], whereas CD22 and the
FcgRIIb receptor have been suggested to be inhibitors of
BCR signalling [3–5]. Accessory molecules can recruit
additional signal-transducing proteins to the antigen
receptor, using their cytoplasmic tails. In this way, the
strength of the signal or the threshold of antigen required
for signalling through the antigen receptor can be modu-
lated. Thus, accessory surface proteins can modify the
outcome of the B-cell response, which may vary from the
induction of antigenic tolerance to the production of high-
affinity antibodies.
CD22 is a B-cell specific membrane-bound protein. Upon
BCR-crosslinking, CD22 associates with the BCR and is
phosphorylated on tyrosine residues within its cytoplasmic
tail [6–8]. The cytoplasmic region of CD22 contains six
tyrosine residues, three of which are found within
immunoreceptor tyrosine-based inhibitory motif (ITIMs).
These recently identified motifs are characterized by the
sequence Val/Iso–X–Tyr–X–X–Leu (where X is any amino
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acid) [9]. The tyrosine phosphatase SHP-1 (also known as
PTP1C, HCP or SHPTP1) is a negative regulator of sig-
nalling in haematopoietic cells [10], which can bind to the
phosphorylated ITIM of CD22 in vitro and become acti-
vated [3]. It was shown in vitro that CD22 can modulate
BCR-signalling: when B cells were pretreated with beads
coated with anti-CD22, the concentration of anti-
immunoglobulin M (IgM) required for the induction of
proliferation was two orders of magnitude lower. The inter-
pretation of this result was that the BCR was released from
the negative regulation by CD22, mediated by SHP-1
[3]. In similar experiments, the Ca2+ response associated
with B-cell signalling was enhanced following pretreat-
ment of the cells with anti-CD22 [11]. The phosphory-
lated cytoplasmic tail of CD22 can also bind the Src
homology 2 (SH2) domains of Syk and PLCg, which are
important for triggering Ca2+ influx [12]. Thus, treatment
with anti-CD22 may also recruit additional Syk and
PLCg molecules to the plasma membrane, and, in this
way, lower the threshold of signal induction. It has,
however, been difficult to obtain direct proof for the pro-
posed mechanism of the negative regulation of BCR sig-
nalling by CD22. 
Accessory molecules are often involved in cellular adhe-
sion. Lymphocytes can obtain information about their
microenvironment upon binding of their cell-surface
receptors to ligands expressed on other cells. CD22 has
properties of an adhesion molecule and belongs to the
sialoadhesin family of receptors. CD22 can bind to
ligands carrying a2,6 sialic acids expressed at the surface
of several cell types in vitro [13–16]. One ligand for
CD22, identified from studies in vitro, is CD45, a trans-
membrane tyrosine phosphatase expressed on various
haematopoietic cells [17]. The adhesion of CD22 to its
ligands may be regulated by the activity of the enzyme
a2,6 sialyltransferase, which generates the ligand for
CD22 on target cells; this enzyme may also inhibit adhe-
sion by sialylating CD22 itself on the surface of the B
cell [18,19]. 
Recently, mice with a disrupted CD22 gene were
described [20]. B cells isolated from these mice showed an
increased Ca2+ flux after BCR-crosslinking. The CD22
targeted mice gave an augmented T-cell dependent
response, had an expanded peritoneal B-1 cell population
and increased serum titres of autoantibodies [20]. We
describe here the generation and phenotype of a CD22–/–
mouse line obtained with a different targeting construct
that shows similarities, but also clear differences, to the
previously described targeted mouse line.
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Figure 1
(a) Disruption of the CD22 gene. Part of the CD22 locus [21] is
shown before (top) and after (bottom) homologous recombination with
the targeting vector (middle). The exons (black boxes) and the probe
are indicated. A neomycin resistance gene was inserted into exon 11,
which normally encodes the transmembrane region of the protein. The
HSV-tk gene was added to allow for negative selection against random
integration. B, BamHI; E, EcoRI; H, HindIII. (b) Southern-blot analysis
of ES cell clones. EcoRI or BamHI digests of ES cell DNA from clones
3A, 7F, 2 and 4 (B6 are untransfected ES cells) are shown. The
fragments derived from the wild-type or targeted allele are indicated as
wt or targ, respectively. (c) Flow-cytometric analysis of spleen cells
stained with anti-CD22. Splenic cells of CD22–/– (open curve) and
wild-type mice (filled curve) were stained with anti-CD22 and analyzed
by flow cytometry.
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Results
Disruption of the CD22 gene
The targeting vector for the CD22 locus was constructed
from polymerase chain reaction (PCR) products obtained
from C57Bl/6 DNA. The coding sequence of the CD22
gene was disrupted by insertion of a neomycin cassette
into exon 11; this exon normally encodes the transmem-
brane domain of the protein [21] (Fig. 1a). After transfec-
tion of the targeting vector, embryonic stem (ES) cell
clones of C57Bl/6 origin [22] that had undergone a proper
targeting event were obtained (Fig. 1b). Subsequently,
chimaeric mice were generated that transmitted the muta-
tion into the germline, and the offspring of these chimaeric
mice were then bred to homozygosity. Homozygous
mutant mice lack surface expression of CD22 as shown by
flow-cytometric analysis of CD22-stained splenocytes
(Fig. 1c). Two independent CD22–/– mouse lines, derived
from the ES cell clones 3A and 7F (Fig. 1b), were gener-
ated, which were phenotypically indistinguishable. 
CD22–/– mice show normal B-cell development, but their
splenic B cells have a more mature phenotype
The lack of surface expression of CD22 on the spleno-
cytes of homozygous mutant mice allowed us to study its
expression more precisely in the wild-type mouse. In con-
trast to other reports [23,24], we find that CD22 is
expressed as a surface molecule from the pre-B to the
mature B-cell stages, with higher levels on more mature B
cells (Fig. 2a,c). Bone marrow cells of RAG2–/– mice are
CD22-negative (data not shown), indicating that CD22
begins to be expressed on the surface of pre-B cells after
initiation of rearrangement of the V, D and J segments of
the BCR gene locus. 
Although CD22 is expressed from an early stage in devel-
oping B cells of wild-type mice, B-cell development in
CD22–/– mice was normal. In the bone marrow, pre-B cells
(IgM–B220lo), immature (IgMloB220lo) and transitional
[25] (IgMhiB220lo-hi) B cells were found in a normal distri-
bution and in normal numbers (Fig. 3a,b and Table 1).
However, the population of mature B cells (IgMloB220hi or
IgD+) was strongly reduced (Fig. 3b,d; also see below). In
the peripheral compartment, B cells and T cells were
found in normal numbers (Table 1). In the spleen,
however, the phenotype of the B cells was abnormal.
CD22–/– mice had reduced numbers of transitional B cells
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Table 1
Cell number of CD22–/– mice.
Bone marrow (total cells) B220+IgM– B220+IgM+ Spleen (total cells) B220+IgM+
+/+ (18 ± 7) x 106 (3.6 ± 0.4) x 106 (1.5 ± 0.4) x 106 (84 ± 20) x 106 (45 ± 4) x 106
–/– (18 ± 6) x 106 (3.8 ± 0.4) x 106 (1.4 ± 0.3) x 106 (91 ± 24) x 106 (47 ± 5) x 106
Peritoneal cavity (total cells) IgM+CD5+ IgM+CD5– Lymph node (total cells) B220+IgM+
+/+ (2.2 ± 0.4) x 106 (0.4 ± 0.1) x 106 (0.7 ± 0.1) x 106 (20 ± 5) x 106 (7.2 ± 1) x 106
–/– (2.0 ± 0.8) x 106 (0.5 ± 0.2) x 106 (0.6 ± 0.2) x 106 (21 ± 8) x 106 (6.7 ± 1) x 106
Flow-cytometric analysis of age- and sex-matched CD22–/– and control mice. Mice were 6 to 10 weeks old. The numbers are means from six mice
per group for spleen and bone marrow (two femurs per mouse) or four mice per group for peritoneal cavity and lymph nodes (submandicular, axial,
inguinal and para-aortic).
Figure 2
Expression pattern of CD22 in bone marrow cells. The flow cytometric
analysis of wild-type (+/+) and CD22–/– (–/–) bone marrow cells
stained with CD22 versus B220 is shown in the upper panels; CD22+
and CD22– B cells are framed. In the lower panels, the distribution of
bone marrow cells in CD22loIgM– (most of the pro- and pre-B cells),
CD22loIgM+ (immature B cells) and CD22hiIgMlo (mature B cells) is
depicted and the percentages of the populations are given.
Transitional B cells (CD22lo-hiIgMhi) are not separately boxed.
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(IgMhiIgDlo) [25] and the overall expression of membrane-
bound mIgM (mIgM) was half the level of that in wild-
type mice (Fig. 3e,f). However, CD22–/– splenic B cells
expressed twice as many major histocompatibility
complex (MHC) class II molecules (data not shown), but
had normal levels of the pan B-cell marker CD19, of the
adhesion molecules CD24,  VLA-4 and LFA-1, and of the
activation markers CD69, B7.1 and B7.2 (data not shown). 
The lymph node was of normal size in CD22–/– mice
(Table 1), but B cells from these lymph nodes expressed a
lower level of mIgM than in wild-type mice (data not
shown). In the peritoneal cavity, we found normal
numbers of B-1 and B-2 cells (Fig. 3g,h and Table 1). B-1
cells were identified as B220lo, CD5+ or Mac-1+, IgDlo and
B-2 cells were identified as B220hi, CD5– and Mac-1–,
IgD+. In conclusion, most peripheral B cells of CD22–/–
mice were phenotypically similar to mature, resting B
cells, but had lower levels of mIgM (Fig. 3f) and, paradox-
ically, enhanced expression of the activation marker MHC
class II molecules. CD22–/– mice had normal serum
immunoglobulin levels, except in mice older than
5 months, in which IgM levels were twice that found in
control mice (data not shown). 
CD22 is a negative regulator of BCR-induced Ca2+
signalling
The association of CD22 with the BCR and its phosphory-
lation after BCR-crosslinking suggest that CD22 is
involved in signalling from the BCR. We first studied Ca2+
mobilization. Splenic B cells of CD22–/– mice showed an
increased and prolonged influx of Ca2+ after stimulation
with anti-IgM over a wide range of antibody concentra-
tions, when compared with control B cells (Fig. 4).
Although the average density of mIgM was two-fold lower
on CD22–/– B cells (Fig. 3e,f), the threshold for the initia-
tion of Ca2+ flux was at least 10-times lower (Fig. 4). The
response to anti-kappa stimulation, which activates all
surface immunoglobulin receptors, was similarly increased
(data not shown). The increased Ca2+ flux found in
CD22–/– B cells is similar to results obtained with SHP-1– B
cells of motheaten mice [26]. As CD22 can bind and activate
SHP-1 in vitro [3], these results suggest that CD22 medi-
ates the negative regulation of the BCR signal through
stimulation of the tyrosine phosphatase activity of SHP-1. 
Because tyrosine-phosphorylated CD22 can engage and
recruit the tyrosine phosphatase SHP-1, as well as the tyro-
sine kinase Syk [3,12], tyrosine phosphorylation of sub-
strates in CD22–/– B cells was analyzed. The overall pattern
and kinetics of tyrosine phosphorylation by anti-kappa
stimulation was not greatly changed in CD22–/– B cells, with
exception of the lack of induction of a substrate of 150–160
kDa, which probably corresponds to CD22 [23] (Fig. 5).
Two proteins, which we interpret to be Iga and Igb by
their size, were phosphorylated with the same kinetics in
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Figure 3
Flow cytometric analysis of cells from wild-type (+/+) or CD22–/– (–/–)
mice. The analysis of bone marrow cells is shown in (a–d): (a,b)
populations of pre-B (IgM–B220lo), immature (IgMloB220lo), transitional
(IgMhiB220lo-hi) and mature B cells (IgMloB220hi) are framed and
percentages shown; (c,d) mature cells (IgDhiB220+) are framed. The
analysis of spleen cells is shown in (e,f), indicating the percentages of
IgDhiIgMlo and IgDloIgMhi cells in the boxes. The analysis of peritoneal
cavity cells is shown in (g,h), indicating the percentage of B-1
(IgMhiCD5+) and B-2 (IgMloCD5–) cells in the quadrants.
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CD22–/– and in normal B cells (Fig. 5). In immunoprecipita-
tions, we could detect normal tyrosine phosphorylation of
Syk in CD22–/– B cells (data not shown). Thus, CD22–/–
cells are hyperresponsive with respect to Ca2+ mobilization,
but not with respect to general tyrosine phosphorylation. 
CD22–/– B cells show a higher degree of apoptosis after
anti-IgM treatment and a hyperproliferative response to LPS
As the strength of Ca2+ mobilization has been connected
with induction of apoptosis [26], we compared the survival
of CD22–/– and normal B cells after BCR-crosslinking. We
first treated CD22–/– and normal B cells with goat anti-IgM
in medium containing foetal calf serum low in mitogenic
factors. This treatment resulted in induction of apoptosis,
as measured by the appearance of nuclei containing less
than diploid (2N) DNA content (Fig. 6a). More apoptosis
was induced in CD22–/– than in wild-type B cells, particu-
larly at lower anti-IgM concentrations (Fig. 6a). 
We then asked whether CD22–/– B cells could be rescued
from their propensity to apoptosis by other signals. We
measured cell numbers and thymidine incorporation after
treatment with anti-IgM in the presence of IL-4, with
anti-CD40 or with LPS. Treatment with anti-IgM and
IL-4, or with anti-CD40 induced a similar proliferation of
CD22–/– and normal B cells (Fig. 6b). Surprisingly, LPS
induced a hyperproliferative response in CD22–/– B cells
(Fig. 6b). To differentiate whether the hyperproliferative
response was B-cell autologous or caused indirectly, for
example as a result of a higher sensitivity of CD22–/– B
cells towards macrophage-derived factors, high-density B
cells were then purified. The high-density B-cell fraction
is depleted of macrophages, which are highly responsive
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Figure 4
Ca2+ mobilization in splenic CD22–/– (–/–) and control (+/+) B cells.
The B7-6 antibody (anti-IgM) was added at the concentrations
indicated within each plot. The arrows show the timepoint of antibody
addition. The intracellular Ca2+ concentration ([Ca2+]i) is represented
as the ratio of bound to unbound Indo-1. 
0
20
0
4
00
6
00
8
00
10
00
0
20
0
4
00
6
00
8
00
10
00
0
20
0
4
00
6
00
8
00
10
00
0
20
0
4
00
6
00
8
00
10
00
0
20
0
4
00
6
00
8
00
10
00
0
20
0
4
00
6
00
8
00
10
00
0
20
0
4
00
6
00
8
00
10
00
0
20
0
4
00
6
00
8
00
10
00
+/+ –/–
1 µg ml–1 1 µg ml–1
3 µg ml–1 3 µg ml–1
9 µg ml–1 9 µg ml–1
25 µg ml–1 25 µg ml–1
1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8
[C
a2
+
] i 
(b
ou
nd
:u
nb
ou
nd
 In
do
-1
)
Time (min)
Figure 5
The tyrosine phosphorylation of lysates of splenic B cells stimulated
with goat anti-kappa and immunoblotted with anti-phosphotyrosine
antibody is shown in the upper panel. Control B cells are denoted by
+/+ and CD22–/– cells by –/–. The numbers on the left give molecular
mass in kDa, and the arrows show the expected mobilities for CD22,
Igb (2 bands) and Iga. The blot was stripped and probed with an
antibody against anti-eukaryotic initiation factor-4A as a loading control
(lower panel).
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to LPS. High-density B cells showed an increase in prolif-
eration in response to LPS stimulation, as had been
observed in the total splenic B-cell fraction (Fig. 6b), con-
firming that the higher response to LPS is intrinsic to B
cells. In summary, B cells of CD22–/– mice are more prone
to undergo apoptosis after BCR stimulation. 
CD22–/– B cells have a shorter lifespan
If the propensity to undergo apoptosis is mirrored in vivo,
we would expect to see either a smaller B-cell compart-
ment or an increased replacement of the dead cells. As the
size of the B-cell compartment in CD22–/– mice is normal
(Table 1), we tested the second possibility and performed
labelling experiments with the thymidine analogue BrdU,
which is incorporated into the DNA of dividing cells.
Mice were treated with BrdU for varying periods of time.
We found that the labelling rate of CD22–/– splenic B cells
was at least 50 % higher than in wild-type mice. Treat-
ment of the mice with BrdU for 24 hours resulted in 8 %
BrdU-labelled CD22–/– and 4 % BrdU-labelled normal
splenic B cells; after 3 days of treatment, 21 % of CD22–/–
cells and 15 % of normal B cells were BrdU-labelled.
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Figure 6
Measurement of proliferation and apoptosis in vitro. (a) Apoptosis was
induced by treatment with goat anti-IgM in vitro. Splenic cells of
CD22–/– or normal mice were treated with varying concentrations of
antibody shown on the x axis. After stimulation, the cells were stained
with B220, fixed and labelled with propidium iodide. B220-positive
cells were gated and the percentage of cells with less than 2N DNA
content (apoptotic cells) was determined. The amount of apoptosis
induced is defined as the increase in apoptosis after subtraction of the
background spontaneous apoptosis in the absence of anti-IgM
treatment (the background apoptosis detected was approximately
35 %). (b) The proliferation of splenic B cells of wild-type (black
columns) and CD22–/– (dark grey columns) mice in response to the
stimuli indicated under the histogram is shown as 3H thymidine
incorporation or as cell number. The columns on the right show
responses of high density (hd) or low density (ld) B cells of wild-type
(light grey columns) or CD22–/– (white columns) mice; nd = not done.
The graph shows the means of triplicate samples and the
corresponding standard deviations.
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Figure 7
BrdU treatment of mice. (a) Spleen: gated B220+ splenocytes of
CD22–/– (open curve) or wild-type mice (filled curve) after treatment
with BrdU for 5 days. For normal mice, the percentage of cells were:
BrdU–, 73 %; BrdU+, 27 %. For CD22–/– mice, the percentage of cells
were: BrdU–, 59%; BrdU+, 42 %. (b) Bone marrow: bone marrow cells
of CD22–/– (–/–) and wild-type (+/+) mice treated with BrdU; long-
lived, IgM+BrdU– cells are framed. 
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Treatment for 5 days resulted in 42 % BrdU-labelled
CD22–/– B cells and 27 % BrdU-labelled normal B cells, as
shown in Figure 7a. 
In the lymph nodes, which contain mostly long-lived cells,
a 50 % higher labelling of CD22–/– B cells was also found
(data not shown). However, the same proportions of
CD22–/– and normal B cells were in G0/G1 and G2/M
phases of the cell cycle (data not shown). As the pool of
spleen and lymph node B cells is not increased (Table 1),
we conclude from these data that CD22–/– B cells have a
higher rate of turnover and a shorter average lifespan than
wild-type B cells. The dying cells are replaced by recent
immigrant B cells from the bone marrow, which are cycling
and therefore labelled with BrdU [27]. We have previously
shown that transitional B cells are the primary target of
negative selection [25]. We therefore interpret the partial
loss of this population in CD22–/– mice (Fig. 3e,f) to be the
result of a more extensive negative selection. 
Recirculating B cells are almost absent in the bone
marrow: CD22 may be involved in homing to this organ
We then asked whether the absence of mature, recirculat-
ing cells in the bone marrow was also caused by the
shorter lifespan of CD22–/– B cells. BrdU-labelling experi-
ments confirmed that, in the bone marrow, the pool of
long-lived B cells (IgM+BrdU–) was almost absent in
CD22–/– mice (Fig. 7b). Most bone marrow B cells are
labelled within 5 days of BrdU treatment [27], except for
the small population of mature, recirculating B cells
(B220+IgD+) that were found to be greatly diminished in
the CD22–/– mice (Fig. 3c,d). Thus, whereas peripheral
lymphoid organs had normal levels of B cells in CD22–/–
mice, and a normal number of B cells with a phenotype
similar to that of splenic CD22–/– B cells was found in
peripheral blood (data not shown), there was a reduction
in the pool of recirculating B cells in the bone marrow.
The higher death rate of CD22–/– cells contributes to the
lack of this population in the bone marrow, but it cannot
account for the complete loss of this pool. 
As CD22 has characteristics of an adhesion molecule
[13–16], we examined the possibility that the homing of
CD22–/– B cells to the bone marrow was defective. To this
end, splenocytes of CD22–/– and wild-type mice were
transferred into RAG2–/– mice [28]. While the spleens of
the recipients were populated equally well by the trans-
ferred cells, there was a significantly lower number of
CD22–/– B cells in the bone marrow compared with control
B cells (0.13 % versus 0.22 %) (Fig. 8). These data imply
that CD22 is involved either directly or indirectly in
homing of recirculating cells to the bone marrow.
Although CD22–/– B cells have an altered phenotype, we
did not find evidence for a change in the expression levels
of adhesion molecules like CD24, VLA-4 or LFA-1 on the
surface of CD22–/– B cells that could directly explain the
alteration in homing behaviour. Therefore, the homing of
recirculating B cells could be mediated by a specific inter-
action between CD22 and a ligand expressed on bone
marrow endothelial cells. 
T-cell independent responses of CD22–/– mice are
impaired, whereas T-cell dependent responses are normal
To assess the function of the immune system in vivo, we
immunized CD22–/– mice with T-cell dependent and T-
cell independent antigens. Both the primary and sec-
ondary responses to the T-cell dependent antigen
NP-ovalbumin were normal (Fig. 9a), as was expected
from the in vitro stimulation experiments with IL-4 and
CD40. Germinal centres with a normal structure were
generated (data not shown). Also, the memory response
4 months after the initial priming with antigen was normal
(data not shown). These results indicate that CD22 is not
required for interactions between B and T cells that gen-
erate T-cell dependent immune responses and class
switching, as had been proposed following the identifica-
tion of CD45 as a ligand for CD22 [29]. In contrast,
CD22–/– mice showed significantly impaired responses to
the T-cell independent type II antigen TNP-ficoll (Fig.
9b). The response was three-times lower than in control
animals and was seen with three different concentrations
of antigen (data not shown). We interpret these data in the
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Figure 8
Adoptive transfer of CD22–/– and normal splenocytes into RAG2–/–
mice. 24 h after transfer, the number of IgM+IgD+ cells of the recipients
was determined as a percentage of all lymphocytes, which was
defined by scatter profiles. The cells transferred are shown under the
histogram: +/+, from wild-type mice; –/–, from CD22–/– mice; PBS,
control (no cells). Four mice were used in each group (p < 0.05 as
evaluated by student’s t-test).
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light of the lowered threshold for stimulation. A T-cell
independent antigen that causes a high degree of cross-
linking of the BCR may cause deletion rather than stimu-
lation of B cells. By weakening the BCR signal, CD22 may
allow an efficient response to bacterial carbohydrate anti-
gens with repetitive structures such as T-cell independent
type II antigens. Therefore, CD22 apparently comple-
ments the role of CD19, which is important for T-cell
dependent, but not T-cell independent immune
responses [30].
Discussion
In a recent paper [20], a CD22–/– mouse line was described
which showed similarities, but also differences, with the
CD22–/– mouse line described here. The results reported
by O’Keefe et al. [20] are in full agreement with ours
regarding the phenotype of splenic B cells and as to the
functional properties of isolated B cells in vitro. However,
analysis in vivo revealed major differences. Our CD22–/–
mice gave normal responses to T-cell dependent antigens,
had normal numbers of B-1 cells and, up to the age of
11 months, they showed no signs of autoimmune disease.
This contrasts with the CD22–/– mice reported by O’Keefe
et al., which demonstrated higher T-cell dependent anti-
body responses, an increased number of B-1 cells and pro-
duction of autoantibodies. Induction of apoptosis, lifespan
of B cells and T-cell independent responses were not
studied by O’Keefe et al. [20]. The differences in pheno-
type could well be explained by a residual CD22 expres-
sion or by mouse strain differences. Our targeting
construct, which deleted parts of exon 11, cannot produce
a CD22 molecule with a truncated cytoplasmic tail as
aberrant splicing of mRNAs to any of the downstream
exons would not preserve the reading frame. Although we
cannot formally exclude a residual secretion of a truncated
CD22 protein, circumstantial evidence makes this possi-
bility unlikely. The CD22–/– mouse line described here is
on a pure C57Bl/6 background.
The prevailing trait of CD22–/– mice is the increased and
prolonged Ca2+-influx after BCR-crosslinking. There is
good reason to assume that this change in function is the
basis of the phenotype of CD22–/– mice. CD22 is associ-
ated with the BCR and is phosphorylated on tyrosine
residues in its cytoplasmic tail after BCR-crosslinking
[6–8]. Three of the tyrosine residues are arranged in
ITIMs. These motifs are also found in other surface
receptors and exert a negative regulatory function, as has
been shown for the FcgRIIb receptor expressed on B cells
[4,5] and the killer cell inhibitory receptor (KIR)
expressed on NK cells [9]. Co-ligation of the BCR with a
FcgRIIb receptor carrying a mutation in the ITIM gener-
ates a signal that is very similar to that seen in CD22–/– B
cells, and results in no obvious change in the pattern of
tyrosine phosphorylation of cellular proteins and an
enhanced Ca2+ flux [5]. 
In preliminary experiments, we found that inclusion of the
Ca2+ chelator EGTA in the incubation medium lowered
the Ca2+ flux of CD22–/– and normal B cells to the same
extent, suggesting that Ca2+ entry from the extracellular
space is primarily responsible for the enhanced Ca2+ mobi-
lization, as was observed in studies of the FcgRIIb recep-
tor [5]. In addition, B cells from motheaten mice, deficient
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Figure 9
Responses to T-cell dependent and T-cell independent antigens. The
response to a T-cell dependent antigen is shown in (a) in terms of
NP-specific serum IgG1 levels (arbitrary units) at various days after
immunization of wild-type (filled symbols) and CD22–/– mice (open
symbols). Each symbol represents one mouse. The arrows indicate
the time points of immunization. The response to the T-cell
independent type II antigen TNP-ficoll is shown in (b) in terms of anti-
TNP-specific serum IgM levels (arbitrary units) at day 0 and day 5
after immunization of wild-type mice (dark-grey columns) and CD22–/–
mice (light-grey columns). The data shown is the mean and standard
deviation of nine mice from each group (p < 0.01 as evaluated by
student’s t-test).
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for the tyrosine phosphatase SHP-1, have functional
defects similar to those of CD22–/– B cells [26]. This pre-
dicts that SHP-1, or other phosphatases that can bind to
ITIMs (for example, the SH2-containing inositol phos-
phatase SHIP [31]), mediates the damping effect of CD22
on the Ca2+ flux. In the case of the FcgRIIb receptor,
SHIP seems to be more important for the negative regula-
tion of the Ca2+ influx than SHP-1 [31]. If SHIP can also
bind to the ITIMs of CD22, this would explain the higher
Ca2+ influx combined with a relatively unchanged tyro-
sine-phosphorylation pattern in CD22–/– B cells.
Increased Ca2+ fluxes after receptor crosslinking have
been correlated with an increased propensity towards
apoptosis, and, in SHP-1–/– mice, to a more effective
induction of antigenic tolerance through negative selec-
tion [26]. In CD22–/– mice, an increased induction of apop-
tosis was also found after BCR-crosslinking in vitro.
Increased apoptosis in vivo would be reflected in the loss
of those cells that are most susceptible to negative signals
and an enhanced replacement of B cells in the peripheral
compartment. Indeed, the population of B cells that we
have shown to be most sensitive to tolerance induction,
the transitional B cells [25], is reduced in the spleen of
CD22–/– mice. Moreover, we found a 50 % increased
turnover of B cells in the peripheral compartments,
reflecting a shorter average lifespan.
The increased sensitivity to apoptosis had no influence on
T-cell dependent immune responses, as was expected
from the in vitro rescue experiments with IL-4, anti-CD40
or LPS treatment. However, responses to T-cell indepen-
dent antigens were lower. T-cell independent type II anti-
gens are usually repetitive antigenic determinants on a
backbone of varying length that stimulate B cells in the
absence of T cells. Negative selection by repetitive anti-
genic determinants on an indifferent backbone requires a
certain hapten density in order to surpass a signalling
threshold [32]. We interpret the reduced response to T-
cell independent antigens in CD22–/– mice as reflecting
the greater ease with which B cells are negatively selected,
because of the increased signal after BCR-crosslinking in
the absence of T-cell help. This predicts that immune
responses in CD22–/– mice, in particular to T-cell indepen-
dent antigens, but most likely also to T-cell dependent
antigens, are built up with a different set of immunoglobu-
lin V regions than that in the wild-type mouse.
The shorter lifespan of CD22–/– B cells could account for
the low abundance in CD22–/– mice of recirculating B cells
in the bone marrow, which are normally long-lived.
However, we think this cannot account completely for the
decrease in the number of these cells seen in vivo and in
our repopulation experiments. CD22 has been described
as an adhesion molecule [13–15,33] and could function as
a receptor allowing homing of B cells to the bone marrow.
The fact that normal concentrations of serum proteins can
inhibit the adhesive properties of CD22 [34], makes this
model less attractive, but the mechanism could function in
particular environments where the concentration of a spe-
cific CD22 ligand is high. Finally, we cannot completely
exclude the possibility that CD22–/– B cells may have an
altered expression of other adhesion molecules, leading to
the recirculation defect. 
The phenotypic change of CD22–/– B cells is not easily
explained, but it must be mediated by loss of CD22 and is
therefore most likely a reflection of an mIgM-derived
signal, which is normally damped by CD22. Reduction of
the density of mIgM has been described in anergic B cells
[35]. CD22–/– cells differ functionally from anergic B cells,
however, which do not show Ca2+ fluxes after BCR-
crosslinking, respond poorly to LPS and fail to phosphory-
late Iga and Igb after BCR-crosslinking [36]. We further
found no evidence for a modulation of the expression of
B7.1 and B7.2 after culture in vitro, as has been described
for anergic B cells [36]. More likely, the phenotype of
CD22–/– B cells is the result of chronic basal stimulation
through the BCR. This could explain both the enhanced
responsiveness to LPS and the phenotypic changes of the
B cells. We are currently testing the hypothesis that low-
level activation of downstream effectors of the signalling
cascades, like the mitogen activated protein kinase cascade,
could change the expression level of specific genes. 
Materials and methods
Gene targeting
The targeting vector was constructed by PCR amplification of B6 III ES
cell DNA using semi-nested PCR. A 2.8 kb fragment from exon 8 to 11
was amplified with the following primers: 5′ GACGTCACCTCCTACA-
GATG; 5′ AGAGGATCCATGCCTGTCAGCTGT (both exon 8) and
5′ ACAGTCGACGCAGAAGCCTAGTCCAA (exon 11). A 1.5 kb frag-
ment from exon 11 to exon 15 was amplified with the primers: 5′ ACT-
GTCGACTCTTCATCCTGGCCATCT (exon 11) and
5′ GTTGGAGAAGCAGACGTGGC; 5′GGAGGATCCCCAGCCAGA-
GAAGGCC ( both exon 15). The primers for exon 11 were tagged with
a 5′ SalI restriction site, which was used for inserting the neomycin resis-
tance gene (pMCneoPolyA, Stratagene). ES cell culture and screening
was carried out as described [37], with the exception that clones were
transferred onto 96-well plates, trypsinized and split into two samples;
one sample was plated on 48-well plates, and the other was lysed on the
plates for PCR analysis. For electroporation of ES cells, the targeting
vector was linearized with PvuI within the vector backbone.
Flow cytometry and BrdU labelling
Flow cytometric analysis of bone marrow, spleen and peritoneal cavity
is representative of at least three independent experiments, which were
carried out with groups of two CD22–/– and two CD22+/+ littermates of
6–10 weeks of age. Cell suspensions were stained with the following
antibodies: Phycoerythrin (PE)- and fluorescein (FITC)-RA3-6B2 (anti-
B220), FITC-B7-6 (anti-IgM), PE-goat F(ab′)2 anti-IgM (Caltag), biotin-
11-26C (anti-IgD), PE-anti-CD22 (Clone Cy34.1, Pharmingen),
FITC-anti-BrdU (Becton Dickinson) and biotin-anti-CD5 (Pharmingen).
Biotinylated antibodies were detected with streptavidin-Red670
(Gibco BRL). For BrdU labelling experiments, mice were given
1 mg ml–1 BrdU (Boehringer Mannheim) into the drinking water for
5 days. The anti-BrdU staining was done as described [38]. The BrdU
experiment shown is representative of three independent experiments.
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Measurement of Ca2+ influxes
Splenic B cells were loaded with Indo-1 and stained with FITC-anti-
Mac1 and biotin-anti-Thy-1, followed by streptavidin-PE. For flow cyto-
metric analysis of Ca2+ release, only Mac1- and Thy-1-negative cells (B
cells) were analysed. The results are representative for four indepen-
dent experiments.
Induction of tyrosine phosphorylation
Splenic lymphocytes were depleted of T cells with GK1.5 (anti-CD4),
AT83A (anti-Thy1) and 19-178 (anti-CD8), followed by rabbit comple-
ment at 37 °C for 45 min. The remaining cells were starved for 1 h in
medium without FCS at 37 °C, stimulated with 10 mg ml–1 goat anti-
kappa (Southern Biotechnology Associates) and then lysed [39]. After
electrophoresis, the gel was blotted and stained with anti-phosphotyro-
sine antibody 4G10 (Upstate Biotechnology) and developed with goat
anti-mouse IgG-horse radish peroxidase (Southern Biotechnology
Associates). The experiment shown is representative of three indepen-
dent experiments.
Measurement of proliferation
Splenic lymphocytes were prepared and depleted of T cells as
described above. B cells were cultured in Iscove’s medium at
5 × 105 ml–1 (Fig. 4c) or 1 × 106 ml–1 (Fig. 4d) supplemented with
25 mg ml—1 B7-6 (anti-IgM) plus 500 U ml–1 IL-4 (Pharmingen);
1 mg ml–1 anti-CD40 (Pharmingen) or with 15 mg ml–1 LPS EH100 (a
generous gift of Dr. Galanos) for 48 h. Proliferation was measured by
3H thymidine incorporation (2 mCi per well) during the last 6 h of
culture (measurements made using an Inotech Trace 96 counter). One
part of the experiment was done with percoll-purified fractions of high-
density (hd) or low-density (ld) B cells which were prepared as
described [40]. The high-density fraction contained less than 0.5 %
Mac-1hi cells (as judged by flow cytometry). The results are representa-
tive of three independent experiments.
Measurement of apoptosis after anti-IgM treatment
Splenocytes of CD22–/– or normal mice were treated for 24 h with goat
anti-IgM in vitro. They were stained with FITC-anti-B220 and fixed in
70 % ethanol at 4 °C overnight. The fixed splenocytes were then treated
with 10 mg ml–1 RNAse at 37 °C for 30 min and stained with 25 mg ml–1
propidium iodide. The data are representative of two experiments.
Adoptive transfer into RAG2–/– mice
1 × 107 splenocytes of CD22–/– or normal mice were injected intra-
venously into RAG2–/– recipients. After 24 h, the recipient animals
were killed, and spleen and bone marrow cells were analyzed by flow
cytometry. The experiment shown is representative of two independent
experiments.
Immunizations
CD22–/– mice and normal littermates of 8–12 weeks of age were
immunized with TNP-ficoll intraperitoneally (nine mice per group) or
with 100 mg alum-precipitated NP-ovalbumin together with bordatella
pertussis as adjuvant. Enzyme-linked immunosorbant assays were
carried out using TNP-BSA or NP-BSA coated plates, respectively, as
described [41]. The results shown are each representative of two inde-
pendent experiments. A second T-cell dependent antigen DNP-ovalbu-
min was used with similar results.
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